ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 164 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2016. The put-call ratio across all filers is 1.13 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,786,646 | -17.5% | 947,732 | +6.8% | 0.02% | 0.0% |
| Q2 2023 | $40,951,031 | +15.0% | 887,731 | -0.1% | 0.02% | +10.0% |
| Q1 2023 | $35,617,663 | -10.8% | 888,221 | +3.1% | 0.02% | -13.0% |
| Q4 2022 | $39,921,587 | +16.2% | 861,679 | +3.9% | 0.02% | +9.5% |
| Q3 2022 | $34,357,000 | +18.1% | 829,667 | +70.1% | 0.02% | +31.2% |
| Q2 2022 | $29,096,000 | +9.6% | 487,708 | +33.4% | 0.02% | +33.3% |
| Q1 2022 | $26,545,000 | -30.7% | 365,528 | -19.7% | 0.01% | -29.4% |
| Q4 2021 | $38,288,000 | +19.3% | 455,333 | +28.0% | 0.02% | +13.3% |
| Q3 2021 | $32,089,000 | -11.2% | 355,786 | -6.1% | 0.02% | -16.7% |
| Q2 2021 | $36,127,000 | -25.7% | 378,881 | -11.2% | 0.02% | -30.8% |
| Q1 2021 | $48,602,000 | -23.7% | 426,846 | -7.2% | 0.03% | -33.3% |
| Q4 2020 | $63,706,000 | +79.5% | 460,204 | +6.6% | 0.04% | +62.5% |
| Q3 2020 | $35,494,000 | -5.8% | 431,861 | -10.3% | 0.02% | -17.2% |
| Q2 2020 | $37,661,000 | +78.5% | 481,468 | +1.4% | 0.03% | +52.6% |
| Q1 2020 | $21,098,000 | +12.8% | 474,858 | +8.4% | 0.02% | +58.3% |
| Q4 2019 | $18,700,000 | -5.5% | 437,869 | -5.3% | 0.01% | -14.3% |
| Q3 2019 | $19,778,000 | -43.4% | 462,377 | -15.9% | 0.01% | -30.0% |
| Q2 2019 | $34,922,000 | +11.6% | 549,995 | +21.9% | 0.02% | +5.3% |
| Q1 2019 | $31,300,000 | +285.3% | 451,296 | +141.5% | 0.02% | +216.7% |
| Q4 2018 | $8,124,000 | -79.9% | 186,874 | -64.7% | 0.01% | -50.0% |
| Q3 2018 | $40,375,000 | -16.5% | 528,919 | -16.0% | 0.01% | -14.3% |
| Q2 2018 | $48,382,000 | +160.6% | 629,434 | +72.8% | 0.01% | +55.6% |
| Q1 2018 | $18,567,000 | +118.1% | 364,169 | +98.3% | 0.01% | +80.0% |
| Q4 2017 | $8,515,000 | -55.8% | 183,677 | -49.3% | 0.01% | -61.5% |
| Q3 2017 | $19,284,000 | +49.8% | 362,120 | +74.7% | 0.01% | +44.4% |
| Q2 2017 | $12,875,000 | +24.1% | 207,327 | +35.4% | 0.01% | +12.5% |
| Q1 2017 | $10,372,000 | -15.8% | 153,090 | -12.7% | 0.01% | -20.0% |
| Q4 2016 | $12,320,000 | -18.9% | 175,283 | -18.2% | 0.01% | -9.1% |
| Q3 2016 | $15,198,000 | +96.2% | 214,265 | +35.2% | 0.01% | +120.0% |
| Q2 2016 | $7,747,000 | -43.4% | 158,466 | -26.7% | 0.01% | -50.0% |
| Q1 2016 | $13,689,000 | -26.3% | 216,277 | +30.7% | 0.01% | -23.1% |
| Q4 2015 | $18,565,000 | +81.3% | 165,526 | +55.6% | 0.01% | +62.5% |
| Q3 2015 | $10,239,000 | +60.0% | 106,353 | +70.1% | 0.01% | +100.0% |
| Q2 2015 | $6,399,000 | +102.2% | 62,518 | +22.6% | 0.00% | +100.0% |
| Q1 2015 | $3,165,000 | +316400.0% | 51,003 | +145622.9% | 0.00% | – |
| Q4 2014 | $1,000 | -99.3% | 35 | -98.7% | 0.00% | – |
| Q3 2014 | $150,000 | +117.4% | 2,685 | +74.4% | 0.00% | – |
| Q2 2014 | $69,000 | -93.5% | 1,540 | -92.9% | 0.00% | -100.0% |
| Q1 2014 | $1,067,000 | – | 21,840 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |